FDA Panel Suggests Zero Tolerance For Blood Deposits On Jet Injectors
This article was originally published in The Gray Sheet
Executive Summary
Manufacturers seeking approval for multiple-use nozzle injectors should demonstrate that no detectable blood or serum residues remain on the device after injection, members of the General Hospital and Personal Use Devices Panel advised Aug. 9